Details of the Drug

General Information of Drug (ID: DMEN2L7)

Drug Name
AG019
Indication
Disease Entry ICD 11 Status REF
Type-1 diabetes 5A10 Phase 1/2 [1]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
DL6EZ5

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-10 (IL10) TTT0Q1F IL10_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Type-1 diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-10 (IL10) DTT IL10 1.07E-02 0.08 0.56
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health.